FridayOL

Auckland, New Zealand – BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT), a pioneering clinical-stage biotechnology company, has received a significant boost to its cancer immunotherapy development program with the granting of New Zealand Patent No. [Insert Patent Number Here]. This patent safeguards a crucial element of BriaCell’s proprietary whole-cell technology, marking a key milestone for the company and reinforcing its commitment to revolutionizing cancer treatment.

What is BriaCell's Whole-Cell Technology?

BriaCell's innovative approach centers on harnessing the power of the body's own immune system to fight cancer. Their whole-cell immunotherapy utilizes engineered cancer cells, which, when administered to patients, act as potent vaccines. These vaccines stimulate a robust immune response, effectively training the body to recognize and destroy cancer cells throughout the body, not just those present at the initial injection site. This unique approach has the potential to offer a more comprehensive and durable response compared to traditional cancer therapies.

Why is this New Zealand Patent Important?

Securing this patent in New Zealand provides BriaCell with exclusive rights to their technology within the country. This is strategically important for several reasons:

• Intellectual Property Protection: The patent strengthens BriaCell's overall intellectual property portfolio, protecting their investment in research and development.
• Market Access: New Zealand represents a valuable market for potential future commercialization of BriaCell’s therapies, and the patent solidifies their position.
• Investor Confidence: The granting of the patent demonstrates the novelty and inventiveness of BriaCell's technology, bolstering investor confidence and attracting further investment.
• Global Strategy: This patent contributes to BriaCell's broader global strategy of securing intellectual property rights in key markets worldwide.

Looking Ahead for BriaCell

BriaCell is currently focused on advancing its lead immunotherapy candidate, BC-1, through clinical trials. BC-1 is being evaluated in patients with HER2-positive breast cancer and other solid tumors. The company anticipates that the New Zealand patent will further support the development and potential commercialization of BC-1 and future whole-cell therapies.

“We are delighted to announce the granting of this New Zealand patent,” said [Insert CEO Name and Title Here]. “This achievement underscores the significant potential of our whole-cell technology and reinforces our commitment to developing innovative immunotherapies that can transform the lives of cancer patients. We believe this patent is a vital step in realizing our vision of a future where cancer is effectively managed and patients experience improved outcomes.”

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company dedicated to developing novel immunotherapies for cancer. Their focus is on leveraging the body's own immune system to fight cancer, with a proprietary whole-cell technology platform. The company’s lead candidate, BC-1, is currently in clinical trials.

Disclaimer: [Insert standard company disclaimer regarding forward-looking statements here]